Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Price:
19.1
USD
4.26%
Market Closed
Market Cap:
$526.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
|
US |
|
Orge Enerji Elektrik Taahhut AS
IST:ORGE.E
|
TR |
|
I
|
Iyogin Holdings Inc
TSE:5830
|
JP |
|
Alpha Lithium Corp
XTSX:ALLI
|
CA |
|
Ekso Bionics Holdings Inc
NASDAQ:EKSO
|
US |
|
Rolls-Royce Holdings PLC
LSE:RR
|
UK |
|
YG Plus Inc
KRX:037270
|
KR |
|
M
|
Mercedes-Benz Group AG
LSE:0NXX
|
DE |
|
Clearford Water Systems Inc
XTSX:CLI
|
CA |
|
H
|
Hi Score Corp
OTC:HSCO
|
US |
Multiples-Based Value
The
Multiples-Based Value for
Crescent Biopharma Inc (Pre-Reincorporation) (CBIO)
under the Base Case is
hidden
USD.
Compared with the current market price of 19.1 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CBIO Multiples-Based Value
LOCKED
Multiples Across Competitors
CBIO Competitors Multiples
Crescent Biopharma Inc (Pre-Reincorporation) Competitors
Crescent Biopharma Inc (Pre-Reincorporation) Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
|
526.3m USD | 48.5 | -3.4 | -2.2 | -2.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
375.5B USD | 6.1 | 89.7 | 14.8 | 20.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.2 | 24.8 | 14.4 | 14.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.7B USD | 6 | 20.7 | 12.9 | 16 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD | 9.5 | 28.7 | 21.6 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD | 5.7 | 18 | 13.5 | 15.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.8 | 37.9 | 40.9 | 41.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3 | 33.1 | 11.1 | 14 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
